Zolgensma® data including patients with more severe SMA at baseline further demonstrate therapeutic benefit, including prolonged event-free survival, increased motor function and milestone achievement

  • Nearly two-thirds of patients (65.6%) in STR1VE-EU have already achieved developmental motor milestones not observed in the natural history of SMA Type 1 at a mean duration of follow-up of 10.6 months, including patients with a more severe phenotype compared to previous studies
  • Two-thirds of patients (66.7%) were free of feeding support, an important indicator of stabilization/halting of disease progression
  • New interim Phase 3 STR1VE-EU data presented at WMS support the robust clinical evidence that …
/by